Preclinical studies showed that bimiralisib suppresses proliferation and induces apoptosis in NOTCH1-mutant HNSCC models with dual PI3K/mTOR inhibition, proving more effective than targeting either pathway alone in HNSCC [67]. Here, PIK3CA is linked to head and neck squamous cell carcinoma.